Monday, January 4, 2010

Revance Confirms $25M Fundraising

Newark-based Revance Therapeutics announced today that it has raised $25M in the first close of a $35M, Series D financing round, confirming information first disclosed in a regulatory filing last week. According to Revance, the new funding was led by Essex woodlands Health Ventures Fund VIII, and also included Essex Woodlands Fund V, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Bio*One Capital and Pac-Link Ventures. Revance is developing aesthetic medicine products, with a lead product aimed at reduce's crow's feet wrinkles. The firm said it expects to close out its round in approximately ninety days. Ron Eastman, Managing Director at Essex Woodlands, joins the firm's board along with the new funding. More information »